Eosinophilic Pneumonia Induced by Medications: An Analysis of Real-World Data from FAERS and Vigibase Identifying Safety Signals and Risk Trends - Takeaways - MDSpire

Eosinophilic Pneumonia Induced by Medications: An Analysis of Real-World Data from FAERS and Vigibase Identifying Safety Signals and Risk Trends

  • By

  • Jing Hu

  • Yao Sun

  • Cong Cheng

  • Sisi Wang

  • Xiangrong Zuo

  • Yun Liu

  • April 22, 2026

  • 0 min

Share

  • 1

    Eosinophilic pneumonia (EP) is a rare lung disease characterized by eosinophil accumulation, often misdiagnosed and linked to medications.

  • 2

    The study analyzed 15,374 cases of drug-induced EP from FAERS, with a high incidence in individuals aged 45 to 64 years.

  • 3

    Daptomycin, nivolumab, and pembrolizumab were the most reported drugs associated with eosinophilic pneumonia.

  • 4

    Factors such as higher body weight, advancing age, and polypharmacy were identified as associated with drug-induced EP.

  • 5

    Early drug discontinuation and corticosteroid therapy are crucial for improving outcomes in eosinophilic pneumonia cases.

Original Source(s)

Eosinophilic Pneumonia Induced by Medications: An Analysis of Real-World Data from FAERS and Vigibase Identifying Safety Signals and Risk Trends

  • by Jing Hu, Yao Sun, Cong Cheng, Sisi Wang, Xiangrong Zuo, Yun Liu

  • April 22, 2026

Related Content

Application of deep learning methods in the classification of normal and pneumonia lung images

Postextubation Pneumonia Tops Ventilator Pneumonia

Older age, male sex, underweight status, reduced activities of daily living, and mild consciousness disturbance were associated with postextubation pneumonia in elective surgical patients.

Varicella Pneumonia Requires IV Acyclovir

Case highlights need for early intravenous antiviral treatment in adults with rash and hypoxia